News

XtalPi and EDDC embarks on a new collaboration with the signing of this MoU. This agreement builds and expands from an ongoing collaboration that utilizes AI and automation to accelerate the drug discovery program for non-small cell lung cancer (NSCLC). With XtalPi’s automation resources and AI capabilities complimenting EDDC’s industry know-how in drug discovery and …

XtalPi and EDDC sign MoU, minting new collaboration to empower biomedical innovation with robotics and Large Language Models (LLM) Read More »

EARO turns 3 this year! To mark this occasion, we are excited to share the EARO Review (2020-2022)! EDDC launched EARO (the EDDC Academic Research Organisation) as a service initiative in mid-2020. The goal was to enable early-stage drug discovery in Singapore by creating multiple pathways for the local academic and biotech community to access …

EARO Review (2020 – 2022) – A Review of EARO’s first 3 years Read More »

EDDC has signed a MoU with BioCurate to bring together complementary scientific and business development expertise and explore opportunities for co-development on projects with the potential to enter the market as new commercially viable therapies.

The Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, is pleased to share that a first patient has been dosed at the National Cancer Centre Singapore (NCCS) in the first-in-human trial of EBC-129.

EDDC signed a 5-year MOU with CRH to explore collaborations that leverage the complementary capabilities, platforms and technologies from both partners to accelerate oncology pipeline assets across a range of developmental stages & modalities. Click here to read about it in detail.

Approval has been obtained from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human trial for EBC-129 in patients with solid tumours EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) that is entering clinical development. It is able to selectively target cancer cells across a range of solid tumours. The ADC and the …

First Made-in-Singapore Antibody-Drug Conjugate (ADC) Approved to Enter Clinical Trials Read More »

XtalPi joins hands with Singapore’s national platform for drug discovery and development to discover more effective treatment options for cancer patients worldwide. In this collaboration, XtalPi will leverage its quantum physics and AI-driven platform, while EDDC provides valuable insight and data on the novel NSCLC target, to accelerate the drug discovery process and propel the …

XtalPi and EDDC collaborate in AI-empowered drug discovery program for Non-Small Cell Lung Cancer Read More »

Virtual screening involves the use of in silico methods to screen for potential small molecule binders of a target protein. This process usually starts with computationally docking a virtual library of chemical compounds to assess how the compounds interact with a defined binding site on the target protein. This is followed by scoring to predict …

Computational Chemistry: Virtual screening and drug discovery Read More »

Minister for Trade and Industry, Mr Gan Kim Yong, creating an entry on the computer to insert a 384-well plate into the compound store at EDDC’s High Throughput Screening (HTS) facility.On 19 August 2022, Experimental Drug Development Centre (EDDC) hosted a visit by Minister for Trade and Industry, Mr Gan Kim Yong. This visit was …

Minister for Trade and Industry, Mr Gan Kim Yong, visits EDDC Read More »

The World Health Organisation1 estimates that over 1.5 million people die from tuberculosis (TB) worldwide, making it the second leading infectious disease killer after COVID-19. Caused by the bacterium Mycobacterium tuberculosis, TB is an infectious disease that has plagued humankind for more than 70,000 years2, with an estimated 10 million new cases of TB annually. …

Compounds against Tuberculosis developed by EDDC and NTU out-licensed to Neuro-Horizon Pharma Read More »